Cardiovascular effects of cholecalciferol treatment in dialysis patients – a randomized controlled trial

BMC Nephrology

Table 4 Effect of 6 months cholecalciferol treatment on pulse wave velocity (PWV), augmentation index (AIx), and central diastolic and systolic blood pressure (cDBP, cSBP) in a randomized, placebo-controlled study of 50 patients on dialysis

	Baseline	6 months	P value (difference in response)
PWV (m/s)
Placebo (n = 19)	10.0 ± 2.0	10.1 ± 2.5	0.269
Cholecalciferol (n = 22)	9.7 ± 2.5	10.5 ± 4.0	0.269
AIx (%)
Placebo (n = 22)	26.4 ± 11.5	22.2 ± 11.2^†	0.013
Cholecalciferol (n = 18)	22.1 ± 9.7	24.6 ± 12.7	0.013
cSBP (mmHg)
Placebo (n = 22)	127 ± 24	126 ± 26	0.744
Cholecalciferol (n = 18)	128 ± 14	125 ± 17	0.744
cDBP (mmHg)
Placebo (n = 22)	68 ± 11	70 ± 11	0.779
Cholecalciferol (n = 18)	71 ± 9	71 ± 12	0.779

Values are means ± SD or medians with 25 and 75 percentiles in brackets. Statistics are performed with t-test. P values represent the probability of a difference in response to treatment between groups: Significant difference from baseline: ^† = p < 0.05.

ISSN: 1471-2369